StockWatch
·

DOMS Industries Ltd Q2 FY27 Results

DOMSQ2 FY27 Results
Filing
Result:Weak· Market: Up#Margin squeeze

Beat/Miss: Miss · Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue667.750.4%17.6%
Total Income672.510.3%17.1%
Expenditure611.170.4%24.1%
PBT50.9516.7%37.7%
Net Profit38.3215.4%37.0%
OPM10.84%1.47pp6.68pp
NPM5.70%1.01pp4.90pp
EPS6.1216.5%36.3%
View full financials

Revenue grew a healthy 17.6% YoY (beating PL's ₹550cr estimate), but adjusted PAT fell 37% YoY to ₹38.3cr on sharp margin compression (OPM 17.5%→10.8%, NPM 10.6%→5.7%), missing the ₹55.2cr consensus PAT estimate by a wide margin.

DOMS INDUSTRIES LTD · Q2 FY-2027 · THE VERDICT

Growth Delivered, Profits Crushed: The Raw Material Squeeze

DOMS posted 17.6% revenue growth to ₹667.8 Cr, meeting FY-2027 guidance. But net profit fell 37% to ₹38.3 Cr as raw material inflation (15%) outpaced pricing power (4–5%). Even after adjusting for the ₹10.4 Cr flooding loss, margins are being crushed — and management's timeline for recovery is now explicitly hedged.

06 Nov 2026 · 6 min read
Reported PAT

₹38.3 Cr

−37.0% YoY

Exceptional loss (flood)

₹10.4 Cr

one-off, recovery status unknown

Adjusted PAT

~₹48.7 Cr

ex-flood; still −20% YoY est.

Revenue

₹667.8 Cr

+17.6% YoY, on FY27 guidance

On the surface, DOMS delivered: revenue growth of 17.6% YoY (₹667.8 Cr) puts the company on-track for FY-2027 full-year guidance of 18–20% growth. But the profit line tells a different story. Net profit crashed 37% to ₹38.3 Cr despite the top-line expansion. Even after adjusting for the ₹10.4 Cr exceptional loss from flooding in Gujarat, the adjusted PAT sits around ₹48.7 Cr — still down roughly 20% year-over-year. This is the quarter's central tension: the company is growing volume and revenue, but profitability is being crushed by raw material inflation that it cannot fully pass through to customers.

The margin squeeze: ₹667.8 Cr of growth, 400 bps of margin loss

EBITDA margin fell to 12.4% in Q2, matching H1, versus the company's stated target of 16–17%. Management disclosed the culprit with rare granularity: raw material cost inflation running at roughly 15% across the stationery and adhesives portfolio, but realized pricing power of only 4–5%. This 1,000 bps gap cannot be closed instantly. With a 2-month inventory buffer and a 3–4 month sales cycle, the company faces a structural lag — it buys raw materials at today's inflated costs, but can only raise customer prices gradually. The arithmetic: ₹667.8 Cr revenue at 12.4% EBITDA margin yields ₹82.8 Cr EBITDA. A historical 16–17% margin would have yielded ₹106.8–₹113.5 Cr EBITDA. The gap is ₹24–30 Cr of EBITDA left on the table due to inflation lag alone.

EBITDA margin, %
06.1612.3218.4812.4Q2 FY27 delivered16.5Historical range16.5Management target
Margin compression of 400–420 bps vs. target. RM inflation at 15% running ahead of pricing power at 4–5%. No visibility to recovery within the quarter.
Management claims vs. what held up

Volume-led growth at 18%-odd, with 80% volume and 20% realization uplift

YoY revenue +17.6%, but RM cost inflation ~15% with only 4–5% pricing pass-through

Overstated

EBITDA margins at 12.4% moving towards 16–17% target

Delivered 12.4% but target 16–17% explicitly acknowledged as near-term unachievable

Contradicted

Sustained revenue growth with healthy volume expansion

H1 FY27 +18.4% YoY revenue, but PAT −37% YoY and margin at 5.7% vs 6%+ historical

Partially supported

Reynolds acquisition accretive from Q3 FY27 onwards

Trial production started; scaling timeline now 'probably 1 year, then 9 months'

Overstated

What changed on this call

Key shifts from prior guidance
  • Margin target explicitly lowered. Prior call hedged guidance; this call admitted 16–17% is near-term unachievable. Recovery timeline pushed to 'couple of quarters' with no specific commitment.

  • Debt nearly doubled. H1 FY27 debt climbed to ~₹200 Cr (from ~₹100 Cr prior year) due to ₹200 Cr capex spend and Reynolds acquisition. H2 capex ₹100–125 Cr planned; total FY27 capex tracking upper end of ₹250–275 Cr.

  • Reynolds timeline slipped. Initial messaging was optimistic; Q&A revealed scaling now 'probably 1 year then 9 months' to revenue contribution. Overhead minimal (~0.5–1% of Q2 sales) but payoff deferred.

  • PAT trajectory deteriorated sharply. Q2 PAT −37% YoY; H1 PAT −37% YoY at 6.2% margin despite 18.4% H1 revenue growth.

The bull-bear ledger

  • Revenue growth delivered. 17.6% YoY (₹667.8 Cr) and 18.4% H1 FY27 puts company on-track for FY27 18–20% guidance. Broad-based across scholastic, office supplies, adhesives, and hobby/craft.

  • Capacity expansion in flight. 50-acre greenfield commissioned. Second & third buildings under way with machinery installation. H2 FY27 expects new scholastic & adhesive capacity online ahead of back-to-school season.

  • New product launches driving mix. Adhesive SKU expansion, scholastic boxes, hobby/craft momentum. Uniclean baby hygiene segment up 21.5% YoY (though margin compressed due to crude inflation).

  • Reported profit leans on exceptional item. ₹10.4 Cr one-off loss from flooding. Even adjusted, PAT down ~20% YoY, masking underlying margin crisis.

  • Margin recovery timeline vague. Management admitted 'very difficult to guide' on margin recovery. Targets 16–17% but offers no specific quarter roadmap. 'Couple of quarters patience' is a hedge, not a commitment.

  • Debt sustainability questioned. Debt doubled to ~₹200 Cr; capex ₹200 Cr H1 + ₹100–125 Cr H2 planned. Margin compression limits cash flow. Management frames debt as 'strategic' but it compresses near-term flexibility.

  • Pricing power constrained. 15% RM inflation vs 4–5% pricing realized. Management tone shifted from confidence to caution — 'measured approach' + 'couple of quarters patience.'

  • Reynolds payoff timing extended. Asset integration complete, trial production started, but scaling timeline extended to 1+ years. Overhead immaterial but revenue contribution deferred.

Ranked risks for a holder

What keeps DOMS holders awake

Raw material inflation persistence & pricing lag

High

15% RM cost inflation vs 4–5% pricing pass-through creates a 1,000 bps structural drag. With 3–4 month sales cycle, if RM inflation continues, margin recovery could slip into FY28. No hedges disclosed.

Margin recovery timeline slippage

High

Target of 16–17% EBITDA now explicitly hedged. If RM inflation persists or pricing doesn't materialize, company will miss guidance. PAT guidance implicitly at risk.

Debt leverage during margin compression

High

Debt at ~₹200 Cr (doubled YoY) with FY27 capex ₹250–275 Cr still in flight. Margin compression at 12.4% reduces cash flow for debt service. If margins stay compressed into FY28, leverage becomes uncomfortable.

Reynolds revenue accretion delay

Medium

Timeline extended to 'probably 1 year then 9 months.' Even if achieved, Q4 FY27 contribution will be minimal. Capex sunk; payoff deferred. If scaling slips further, ROI on capex falls.

Exceptional flood loss & insurance recovery

Low

₹10.4 Cr one-off loss from Q2 Gujarat flooding. Recovery status unknown. If claim denied or delayed, FY27 PAT takes further hit. Already baked into Q2, so near-term impact low.

How the street is positioned (the market's lens)

DOMS shares trade at ₹2050 as of November 5, down 34.2% from an all-time high of ₹3115 but up 14.7% from its 52-week low of ₹1787.7. The stock sits marginally above its 50-day SMA of ₹2075.67 but well below its 200-day SMA of ₹2237.39 — a classic signal of near-term consolidation after a sustained drawdown. RSI at 57 is neutral; volume is increasing, suggesting renewed trading interest but no clear directional conviction.

Institutional positioning is shifting markedly. FII ownership has fallen steadily from 9.08% (Q1 FY26) to 7.50% (Q1 FY27), a drop of 158 basis points. Domestic institutions (DII) have added aggressively, climbing from 16.24% to 25.91%, a gain of 967 basis points. The promoter stake compressed from 70.39% to 63.39%, consistent with the Seven SpA JV formalization (Italian partner FILA acquired 50% of a subsidiary in June 2026 near ₹2200/share). Bulk deals in June 2026 show FILA sold nearly 42.5 lakh shares in the ₹2200 range, while SBI and Axis mutual funds picked up 12.9 lakh shares at similar prices — a classic institutional rotation: foreign sponsor reducing, domestic allocators and mutual funds accumulating.

The street's actual verdict is muted. The stock has not rallied post-result; it has consolidated. This suggests the market priced in the margin squeeze and debt rise before the call. Foreign flows are drying up (FII down 158 bps YoY), which is a red flag for a capital-intensive consumer story asking for patience on margin recovery. Domestic demand (DII + mutual funds) is steady but not enthusiastic — they are not charging in at ₹2050; they are accumulating on weakness. No pop, no panic. The market is waiting for management to either prove pricing power or show clear raw material cost stabilization.

The debate

What to watch next

The 2–3 concrete things that resolve the debate
  • 1 · Q3 FY27 margin recovery (Jan 2027 call)

    The test: Does EBITDA margin expand above 12.4% as back-to-school sales peak and capacity additions ramp? If EBITDA margin exceeds 13% in Q3, pricing action is working. If it stays at 12–12.5%, the 16–17% target is in jeopardy and bears gain traction.

  • 2 · Raw material cost stabilization

    Management flagged RM prices continuing to rise (Oct > Sept). If prices plateau or decline by December, margin headwind eases and pricing lag reverses into a tailwind. Watch industry commentary on pulpwood, crude, resin, and adhesive feedstock availability.

  • 3 · Reynolds revenue contribution & debt paydown timeline

    Trial production started; Q3 FY27 call should clarify ramp trajectory. If Reynolds contributes ₹5–10 Cr+ revenue in Q3/Q4 FY27, capex ROI becomes visible. Separately, watch for management clarity on debt paydown plan. A clear path (₹200 Cr → ₹150 Cr by Q4 FY27) signals confidence in cash flow recovery.

DOMS Industries delivered a quarter that exposes the gap between headline growth and earnings quality. Revenue growth is real and on-track for FY27 guidance. But profit has taken a genuine step down due to raw material inflation that the company cannot fully pass through — a lag structural to its inventory and sales cycle, not a temporary blip. Management's explicit hedge on margin recovery (from 16–17% target to 'couple of quarters' patience) is an honest tell. The real issue is not whether growth will continue — it will — but whether profitability can recover without sacrificing volume. Debt doubling to ₹200 Cr and capex headroom compressed leave little room for error.

The stock at a 34% discount to its all-time high reflects this skepticism. For holders, the question is not 'is DOMS broken?' but 'does management restore margins to 16–17% by Q4 FY27 / Q1 FY28?' For new money, the risk-reward hinges on Q3 FY27 evidence of pricing power or raw material cost stabilization. Until one of those two catalysts emerges, the stock is fairly valued at consolidation. The number to track from here is EBITDA margin — if it expands to 13.5%+ in Q3, the bull thesis re-rates higher. If it stays at 12–12.5%, the bear case (margin pressure persisting into FY28) gains traction.

Informational and educational content only. Not investment advice.